Moderna, Inc. (NASDAQ:MRNA) shares are volatile Monday after the company provided updates on its business and pipeline at the 44th Annual J.P. Morgan Healthcare Conference. The stock’s movement comes as the broader market experiences declines, with major indices like the Dow Jones and S&P 500 under pressure as broader markets edge lower.
- Moderna stock is feeling bearish pressure. Why is MRNA stock falling?
What To Know: Moderna said it expects 2025 revenue of approximately $1.9 billion, which is $100 million above the midpoint previously communicated during its third-quarter earnings call. The company also improved its 2025 expected GAAP operating expenses by $200 million and increased its projected year-end cash balance to approximately $8.1 billion.
For 2026, Moderna reiterated its plan to deliver up to 10% revenue growth and said it expects GAAP operating expenses of approximately $4.9 billion. The company also outlined plans to further reduce operating expenses in 2027 as it works toward targeted cash breakeven in 2028.
Moderna shares initially traded higher on Monday before pulling back and turning negative, per Benzinga Pro.
Moderna highlighted progress across its late-stage pipeline and approved products, noting potential first approvals of its seasonal flu vaccine and flu/COVID combination vaccine beginning in 2026. The company also expects multiple pivotal trial data readouts across oncology, rare disease and infectious disease programs in 2026.
In oncology, Moderna said it continues to advance its personalized cancer vaccine mRNA-4157 in collaboration with Merck, with several Phase 2 and Phase 3 trials ongoing across multiple tumor types. The company also expects potential Phase 2 data readouts in 2026 for its wholly owned cancer antigen therapy mRNA-4359.
Finally, Moderna announced corporate updates, including the closing of a five-year term loan facility for up to $1.5 billion and a funding commitment of up to $54.3 million from the Coalition for Epidemic Preparedness Innovations to support a Phase 3 trial for its investigational H5 pandemic influenza vaccine.
MRNA Price Action: At the time of writing, Moderna shares are trading 3.59% lower at $33.09, according to data from Benzinga Pro.
Image via Shutterstock
Recent Comments